The Latest News and Updates in Acute Myeloid Leukemia

There have been several updates in the field of acute myeloid leukemia (AML) over the last several weeks. Here, CURE® looks back at some of the latest news and updates affecting patients with that cancer type.

• “If this data is positive, then (eprenetapopt) will be approved and this will be the standard of care for patients with (TP53-mutant myelodysplastic syndrome),” said Dr. Guillermo Garcia-Manero in an interview with CURE® where he discussed the phase 3 trial currently investigating eprenetapopt plus Vidaza (azacytidine) in this patient population.
• A health-related quality of life assessment tool, known as Functional Assessment of Cancer Therapy—Leukemia (FACT-Leu), provided a viable and valid outcome measure for patients with AML who are not eligible for intensive therapy.
• The Food and Drug Administration (FDA) has granted a fast track designation to BST-236 (aspacytarabine) to treat adults aged 75 years or older with AML, or who have comorbidities that prevent the use of intensive induction chemotherapy.
• Researchers have found the combination of Tibsovo (ivosenidib) plus Venclexta (venetoclax) — with or without Vidaza (azacytidine) – to be safe and effective in the treatment of patients with IDH1-mutated acute myeloid leukemia (AML), according to the results of a recent trial presented at the 2020 ASCO Virtual Scientific Program.
• The FDA extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive AML.